Pfizer sees coronavirus vaccines as a "durable" business, one executive said recently. But don't expect Pfizer stock to be hung up on Covid-19 in 2021. The company sees plenty of catalysts.
Sarepta Therapeutics' (SRPT) DMD drug sales are rising and pipeline candidates are progressing well. However, dependence on Exondys 51 for near-term growth is a concern.
LOS ANGELES, CA / ACCESSWIRE / January 15, 2021 /The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ:SRPT) for violations of the securities laws.